Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841237 | 1.00 | PREP (0.43) | PREPCASP3CPB1CTSKMEN1 | |
| SCHEMBL3736224 | 0.93 | CPB1 (0.50) | PREPCASP3CPB1CTSKMEN1 | |
| SCHEMBL3736228 | 0.93 | CPB1 (0.50) | PREPCASP3CPB1CTSKMEN1 | |
| SCHEMBL3736230 | 0.93 | CPB1 (0.50) | PREPCASP3CPB1CTSKMEN1 | |
| SCHEMBL2344349 | 0.89 | PREP (0.46) | PREPCASP3CTSKGAACASP1 | |
| SCHEMBL2344340 | 0.89 | PREP (0.46) | PREPCASP3CTSKGAACASP1 | |
| SCHEMBL3625795 | 0.89 | PREP (0.46) | PREPCASP3CTSKGAACASP1 | |
| SCHEMBL13446212 | 0.85 | CASP3 (0.45) | PREPCASP3CTSKMEN1KMT2A | |
| SCHEMBL3250376 | 0.85 | CASP3 (0.47) | PREPCASP3CTSKMEN1KMT2A | |
| SCHEMBL27647296 | 0.84 | CPB1 (0.46) | PREPCASP3CPB1CTSKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671062-B2 | Modulators of chemokine receptor activity, crystalline forms and process | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080027083-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027083-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | ACKR3, CCR1, CCR2 | PREP 1642/4885CASP3 1564/4885CPB1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.